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Summary
Background The vast majority of individuals with familial hypercholesterolaemia in the general population remain 
unidentified worldwide. Recognising patients most likely to have the condition, to enable targeted specialist 
assessment and treatment, could prevent major coronary morbidity and mortality. We aimed to evaluate a clinical 
case-finding algorithm, the familial hypercholesterolaemia case ascertainment tool (FAMCAT), and compare it with 
currently recommended methods for detection of familial hypercholesterolaemia in primary care.
Methods In this external validation study, FAMCAT regression equations were applied to a retrospective cohort of 
patients aged 16 years or older with cholesterol assessed, who were randomly selected from 1500 primary care 
practices across the UK contributing to the QResearch database. In the main analysis, we assessed the ability of 
FAMCAT to detect familial hypercholesterolaemia (ie, its discrimination) and compared it with that of other 
established clinical case-finding approaches recommended internationally (Simon Broome, Dutch Lipid Clinic 
Network, Make Early Diagnosis to Prevent Early Deaths [MEDPED] and cholesterol concentrations higher than the 
99th percentile of the general population in the UK). We assessed discrimination by area under the receiver operating 
curve (AUROC; ranging from 0·5, indicating pure chance, to 1, indicating perfect discrimination). Using a probability 
threshold of more than 1 in 500 (prevalence of familial hypercholesterolaemia), we also assessed sensitivity, specificity, 
positive predictive values, and negative predictive values in the main analysis.
Findings A sample of 750 000 patients who registered in 1500 UK primary care practices that contribute anonymised 
data to the QResearch database between Jan 1, 1999, and Sept 1, 2017, was randomly selected, of which 747 000 patients 
were assessed. FAMCAT showed a high degree of discrimination (AUROC 0·832, 95% CI 0·820–0·845), which was 
higher than that of Simon Broome criteria (0·694, 0·681–0·703), Dutch Lipid Clinic Network criteria (0·724, 
0·710–0·738), MEDPED criteria (0·624, 0·609–0·638), and screening cholesterol concentrations higher than the 
99th percentile (0·581, 0·570–0·591). Using a 1 in 500 probability threshold, FAMCAT achieved a sensitivity of 
84% (1028 predicted vs 1219 observed cases) and specificity of 60% (443 949 predicted vs 745 781 observed non-cases), 
with a corresponding positive predictive value of 0·84% and a negative predictive value of 99·2%.
Interpretation FAMCAT identifies familial hypercholesterolaemia with greater accuracy than currently recommended 
approaches and could be considered for clinical case finding of patients with the highest likelihood of having 
hypercholesterolaemia in primary care.
Funding UK National Institute for Health Research School for Primary Care Research.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Familial hypercholesterolaemia is the commonest 
inherited autosomal dominant disorder and causes 
elevated serum LDL cholesterol from birth.1 It affects 
between 1 in 200 and 1 in 500 individuals in the 
general population,2,3 but the vast majority of cases are 
unrecognised worldwide.4 In the UK, for example, more 
than 80% of an estimated 320 000 individuals remain 
undiagnosed, resulting in major lost opportunities to 
prevent premature heart disease and death.5 If it is 
left untreated, premature coronary heart disease will 
develop in approximately 50% of men with familial 
hypercholesterolaemia by the age of 50 years and about 
30% of women with familial hypercholesterolaemia 
by the age of 60 years.6 Individuals with untreated 
familial hypercholesterolaemia have a 100-fold increase 
in coronary heart disease mortality risk compared with 
the general population.7,8 Such risk can be very effectively 
prevented with high-potency lipid-lowering treatment, 
which can halve coronary heart disease mortality.9
Although clinical cardiovascular risk assessment 
routinely includes serum cholesterol measurement, it 
fails to effectively identify people at increased risk 
of familial hypercholesterolaemia.5 Therefore, inter- 
nationally, case finding for familial hypercholesterolaemia 
is recommended using recognised specialist criteria, such 
as the Dutch Lipid Clinic Network (DLCN), Simon Broome, 
or Make Early Diagnosis to Prevent Early Deaths 
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(MEDPED) criteria.10–12 In addition to these criteria, UK 
guidelines10 suggest that a cholesterol concentration of 
more than 9 mmol/L in individuals older than 30 years 
and more than 7·5 mmol/L for those aged 30 years or 
younger (in line with the 99th percentile for the 
general population) as a starting point for familial 
hypercholesterolaemia case finding. The Simon Broome 
critieria,10 most commonly used in the UK, recommend 
that individuals with a total cholesterol concentration of 
more than 7·5 mmol/L and a family history of premature 
heart disease should be classified as having probable 
familial hyper cholesterolaemia in primary care and 
should be referred for further lipid specialist assessment. 
Patients who then also meet specific clinical diagnostic 
criteria (eg, tendon xanthoma), or diagnosis by genetic 
testing, are categorised as having definite familial hyper- 
cholesterolaemia. The DLCN criteria11 use a points-based 
scoring system to classify possible, probable, or definite 
familial hypercholesterolaemia on the basis of differing 
LDL cholesterol thresholds, family history of premature 
vascular disease and raised cholesterol, personal history of 
premature vascular disease, clinical signs such as tendon 
xanthoma and arcus senilis, or mutation status. The 
MEDPED criteria12 use age-stratified total cholesterol 
thresholds for both the general population and relatives 
depending on degree of relation.
The routine application of DLCN, Simon Broome, or 
MEDPED criteria to patients in generalist clinical 
practice, such as primary care, is a practical challenge 
given the assessments required, including collection of 
detailed family history. Moreover, as many as one in 
four patients in the general population with cholesterol 
concentrations of more than 7·5 mmol/L fulfil referral 
criteria for probable familial hypercholesterolaemia, 
most of whom will not transpire to have definite familial 
hypercholesterolaemia when further assessed by lipid 
specialists13 or genetic diagnosis.14 A simpler and more 
effective clinical case-finding approach to identify 
patients with the highest risk of having familial 
hypercholesterolaemia is needed. Such an approach 
could improve targeted referral for lipid specialist 
assessment and diagnosis, while reducing unnecessary 
referrals, to better detect the vast majority of individuals 
with familial hypercholesterolaemia in the general 
population who remain undiagnosed.
A clinical case-finding algorithm, familial hyper- 
cholesterolaemia case ascertainment tool (FAMCAT), 
has recently been derived and validated using data from 
almost 3 million primary care patients, including more 
than 5000 cases of familial hypercholesterolaemia, from 
the Clinical Practice Research Datalink (CPRD) of 
681 primary care practices in the UK.15 The algorithm had 
high predictive accuracy to identify primary care patients 
with the greatest probability of having familial 
hypercholesterolaemia, with an area under the receiver 
operating curve (AUROC) of 0·86.15 It has begun to be 
integrated in primary care computer systems as a case-
finding tool.16
The majority of clinical algorithms lack well conducted 
and clearly reported external validation.17 We aimed to 
Research in context
Evidence before this study
Familial hypercholesterolaemia is one of the commonest 
inherited disorders in the general population, with 50% of 
people affected developing premature heart disease by 50 years 
of age. More than 80% of an estimated 320 000 individuals in 
the UK remain undiagnosed, resulting in lost opportunities to 
effectively prevent premature heart disease. We searched 
MEDLINE and Embase for research articles published in English 
between Jan 1, 1946, and Sept 15, 2018, using search terms: 
“familial hypercholesterol*”, “diagnos*”, “identif*”, “case 
finding”, “risk algorithm”, “Simon Broom*”, “Dutch Lipid*”, 
“MEDPED”, “FAMCAT”, and “primary care”. We identified 
that most previous studies have used the Simon Broome 
or Dutch Lipid Clinic Network criteria for identification of 
familial hypercholesterolaemia in primary care. Familial 
hyper- cholesterolaemia case ascertainment tool (FAMCAT) 
was the only case-finding algorithm to identify familial 
hypercholesterolaemia that has been developed from a large 
primary care database.
Added value of this study
This study has now externally validated FAMCAT using a 
separate cohort of 747 000 patients from 1500 primary medical 
care practices in the UK, from a different and the world’s largest 
primary care database. FAMCAT is confirmed to have high 
predictive accuracy to detect patients at highest likelihood 
of having familial hypercholesterolaemia in the general 
primary care population and performs better than use of 
Simon Broome, Make Early Diagnosis to Prevent Early Deaths 
(MEDPED), Dutch Lipid Clinic Network criteria, and very high 
cholesterol concentrations alone.
Implications of all the available evidence
The current study underlines the poor predictive accuracy of 
simply using very elevated cholesterol concentrations alone to 
identify familial hypercholesterolaemia, and that specialist 
Simon Broome, MEDPED, and Dutch Lipid Clinical Network 
criteria have relatively lower accuracy than FAMCAT when 
applied to primary care. For clinical case finding of patients in 
primary care with highest likelihood of having familial 
hypercholesterolaemia, FAMCAT is more accurate than other 
approaches and could be used to improve detection of 
familial hypercholesterolaemia in the general population.
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provide external validation of the FAMCAT clinical case-
finding algorithm to identify patients in primary care at 
the highest risk of having familial hypercholesterolaemia. 
We used a separate clinical database, from 1500 UK 
primary care practices, which had no overlap with the 
database from which FAMCAT was derived.
Methods
Study design and population
We did a retrospective cohort study in a large population of 
primary care patients, using the QResearch database. We 
randomly selected, using a random number generator, a 
sample of adult patients aged 16 years or older, who 
registered in 1500 UK primary care practices that 
contribute anonymised data to the QResearch database 
and had at least one documented total or LDL cholesterol 
measurement (necessary for establishing a suspected 
diagnosis). The cohort comprised all patients who were 
actively registered and contributing data (had visited their 
practice up until the end date of when data were 
extracted). For patients who were identified with familial 
hypercholesterolaemia, the date of diagnosis was specified 
as their ending date to ensure all predictors remained 
temporal to their familial hypercholesterolaemia outcome.
Patients aged younger than 16 years were excluded 
from the analysis because cholesterol thresholds for 
diagnosis and treatment of familial hypercholesterolaemia 
in children differ from those for adults.10 Patients 
were also excluded if they had a previous familial 
hypercholesterolaemia diagnosis before the study entry 
date or a diagnosis of other inherited lipid disorders.
The selected baseline registration date corresponded to 
the same starting time used when deriving the FAMCAT 
algorithm using CPRD.15 Moreover, the 750 000 randomly 
selected patient sample was similar to the size of that for 
previous FAMCAT internal validation done in CPRD 
using 742 851 patients, providing a comparable sample 
for external validation.
Predictor variables
FAMCAT was developed as a multivariable logistic 
regression model, stratified by sex, to calculate 
an individual’s probability of having familial hyper- 
cholesterolaemia. The panel summarises all ten predictors 
that were incorporated into FAMCAT. The variables 
were extracted from the QResearch database using UK 
National Health Service (NHS) read code lists (appendix 
pp 6–23) during the study period. Age, cholesterol 
concentrations, and triglycerides were categorised 
(panel). Statin potency was determined using classi- 
fications in the most recent UK National Institute for 
Health and Care Excellence (NICE) lipid modification 
guidelines.18 Secondary causes of raised cholesterol, 
such as diabetes and chronic kidney disease, were 
included as predictor variables for lower probability 
of familial hypercholesterolaemia. Full details of 
FAMCAT development, internal validation, variable 
definitions, effect sizes, and prediction performance are 
published elsewhere.15
Outcomes
The primary outcome was defined as the incident 
diagnosis of familial hypercholesterolaemia, identified 
from a patient record. In the UK, diagnosis of familial 
hypercholesterolaemia is made by lipid specialists 
following clinical assessment using specific diagnostic 
criteria or genetic testing.10 Familial hypercholes- 
terolaemia is then specifically coded in the UK primary 
care coding system by NHS read codes, which are a coded 
hierarchy of clinical terms that provide a standard way by 
which clinicians can record patients’ findings (grouped in 
families of codes) and procedures in information 
technology systems across primary and secondary care. 
In the hypercholesterolaemia family of read codes, the 
familial hypercholesterolaemia code is a specific subcode. 
Statistical analysis
Assuming a population frequency of familial hyper- 
cholesterolaemia between 1 in 500 (0·002) and 
1 in 250 (0·004), to achieve an AUROC of at least 0·80, 
with 90% power and 5% significance requires between 
46 690 (190 positive, 46 500 negative) and 95 190 samples 
(190 positive, 95 000 negative). 
See Online for appendix
Panel: Summary of predictor variables in FAMCAT
• Sex (male or female)
• Age in years (16–24, 25–34, 35–44, 45–54, 55–64, 
65–74, or 75–84)
• Highest cholesterol measurement recorded
• Ideal: total cholesterol ≤5 mmol/L or LDL cholesterol 
≤3·3 mmol/L
• High: total cholesterol 5·1–6·5 mmol/L or LDL 
cholesterol 3·4–4·1 mmol/L
• Very high: total cholesterol 6·6–7·5 mmol/L or LDL 
cholesterol 4·2–4·9 mmol/L
• Extremely high: total cholesterol >7·5 mmol/L or LDL 
cholesterol >4·9 mmol/L
• Triglycerides within 1 month of highest cholesterol 
measurement (mmol/L)
• Ideal: <1·7 mmol/L
• Borderline high: 1·7–2·2 mmol/L
• High: 2·3–5·5 mmol/L
• Very high: ≥5·6 mmol/L
• Lipid-lowering drugs prescribed within 1 month of 
highest cholesterol measurement (none, fibrate, bile acid 
sequestrant, nicotinic acid, low-potency statin, 
medium-potency statin, or high-potency statin)
• Family history of familial hypercholesterolaemia (no or yes)
• Family history of myocardial infarction (no or yes)
• Family history of raised cholesterol (no or yes)
• Type 1 or type 2 diabetes (no or yes)
• Chronic kidney disease (no or yes)
For more on the 
QResearch database see http://
www.qresearch.org
For more on NHS read codes see 
https://data.gov.uk/dataset/
f262aa32-9c4e-44f1-99eb-
4900deada7a4/uk-read-code
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We applied the FAMCAT logistic regression equations 
directly to every patient in the cohort to calculate 
each patient’s probability of having familial hyper- 
cholesterolaemia by use of the untransformed regression 
coefficients and constant terms provided in the 
appendix p 1. We provided descriptive characteristics of 
the study population as patient demographics and clinical 
characteristics. We described continuous normally 
distributed variables by mean and SD, and continuous 
non-normally distributed variables by median and IQR. 
We presented categorical variables as number and 
proportions. We used multiple imputation with chained 
equations to estimate missing values for triglyceride 
measurements (which were sometimes not assessed with 
cholesterol measurements) by generating ten imputed 
datasets.19
We assessed prediction accuracy by examining 
measures of calibration and discrimination. Calibration 
was defined as how closely the predicted probability 
of familial hypercholesterolaemia agrees with the 
expected probability of familial hypercholesterolaemia. 
We assessed calibration by plotting the observed number 
of cases of familial hypercholesterolaemia against 
the predicted number of cases of familial hyper- 
cholesterolaemia for each tenth of predicted probability 
to ensure ten equally sized groups (deciles).
Discrimination was defined as the ability of the 
algorithm to differentiate between patients who were 
predicted to have familial hypercholesterolaemia and 
those who do not have familial hypercholesterolaemia. 
This measure was quantified by calculating the AUROC, 
which is equal to the c statistic (concordance). The 
AUROC value gave the probability that a randomly 
selected patient who has familial hypercholesterolaemia 
has a higher probability score than a patient who does 
not have familial hypercholesterolaemia, ranging from 
0·5 (pure chance) to 1 (perfect discrimination). To 
generate 95% CIs for the AUROC, we used a jack-knife 
procedure20 to estimate SEs.
In the primary analysis, we also compared the 
discrimination of FAMCAT against Simon Broome,10 
DLCN,11 and MEDPED12 diagnostic criteria, and a simple 
classification of total cholesterol concentration higher 
than the 99th percentile10 for determining possible or 
probable familial hypercholesterolaemia. Predictors 
included in the Simon Broome and DLCN criteria were 
extracted using NHS read codes and applied directly to 
the cohort. In a subsequent subgroup analysis, we 
assessed discrimination across various ethnic groups.
As the predicted probabilities of familial hyper- 
cholesterolaemia varied across a continuum, case finding 
for familial hypercholesterolaemia in primary care 
requires decision makers to set a probability threshold. 
The FAMCAT algorithm was shown in an internal 
validation analysis15 to have 70% sensitivity and 
88% specificity when using a probability threshold 
of more than 1 in 500 to determine familial 
hypercholesterolaemia. This threshold  corresponds to a 
conservatively estimated frequency of familial 
hypercholesterolaemia (based on the Hardy-Weinberg 
equation).2 Using the same threshold of more than 
1 in 500, we calculated the sensitivity, specificity, positive 
predictive value, and negative predictive value.
Men (n=362 769) Women (n=384 231)
Familial hypercholesterolaemia diagnosis 485 (0·1%) 734 (0·2%)
Age, years 51·2 (15·7) 52·4 (17·3)
Age during cholesterol measurement, years 54·6 (15·3) 56·5 (16·8)
History of premature myocardial infarction* 12 712 (3·5%) 4333 (1·1%)
Ethnicity
White, white British, or other white 189 239 (52·2%) 210 914 (54·9%)
Asian, Asian British, or other Asian 5361 (1·5%) 6011 (1·6%)
Black, black British, African, or Caribbean 9231 (2·5%) 11 204 (2·9%)
Mixed or multiple ethnic groups 17 454 (4·8%) 16 847 (4·4%)
Other ethnic group 12 137 (3·3%) 13 320 (3·5%)
Unknown or not recorded 129 347 (35·7%) 125 935 (32·8%)
Lipid profile
Highest total cholesterol recorded, mmol/L 5·6 (1·2) 5·8 (1·3)
Highest LDL cholesterol recorded, mmol/L 3·2 (1·1) 3·2 (1·0)
Triglycerides during cholesterol measurement, 
mmol/L†
2·2 (1·7) 1·7 (1·2)
Lipid-lowering drug usage at time of cholesterol measurement
Prescribed fibrate, bile acid sequestrant, or nicotinic 
acid
885 (0·2%) 731 (0·2%)
Prescribed low-potency statin 4739 (1·3%) 3658 (1·0%)
Prescribed medium-potency statin 16 669 (4·6%) 13 431 (3·5%)
Prescribed high-potency statin 5597 (1·5%) 3848 (1·0%)
Family history
Family history of familial hypercholesterolaemia 949 (0·3%) 1526 (0·4%)
Family history of raised cholesterol 2554 (0·7%) 3718 (1·0%)
Family history of myocardial infarction 11 300 (3·1%) 13 499 (3·5%)
Secondary causes of high cholesterol at time of cholesterol measurement
Diabetes diagnosis 54 680 (15·1%) 44 834 (11·7%)
Chronic kidney disease diagnosis 32 551 (9·0%) 43 911 (11·4%)
Data are n (%) or mean (SD). *Premature is defined as younger than 55 years in men and younger than 60 years in 
women. †Data missing for 116 532 (15·6%) of 747 000 participants. 
Table 1: Characteristics of patients aged 16 years from the validation cohort
AUROC SE* 95% CI
FAMCAT 0·832 0·006 0·820–0·845
Simon Broome criteria† 0·694 0·007 0·681–0·703
Dutch Lipid Clinic Network criteria‡ 0·724 0·007 0·710–0·738
MEDPED criteria§ 0·624 0·007 0·609–0·638
Cholesterol concentration higher than the 99th percentile¶ 0·581 0·005 0·570–0·591
AUROC=area under the receiver operating curve. FAMCAT=familial hypercholesterolaemia case ascertainment tool. 
MEDPED=Make Early Diagnosis to Prevent Early Deaths. *Jack-knife procedure to estimate SEs.20 †Total cholesterol 
>7·5 mmol/L or LDL cholesterol >4·9 mmol/L and family history of premature myocardial infarction.10 ‡Score based on 
LDL cholesterol, family history, clinical history, and physical examination.11 §Age-stratified total cholesterol thresholds 
for the general population.12 ¶Total cholesterol >9·0 mmol/L or LDL cholesterol >6·6 mmol/L if age was older than 
30 years; total cholesterol >7·5 mmol/L or LDL cholesterol > 4·9 mmol/L if age was 30 years or younger.10
Table 2: Model discrimination in the external validation cohort for identification of familial 
hypercholesterolaemia in primary care (n=747 000)
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In a post-hoc analysis, we also calculated the sensitivity, 
specificity, positive predictive value, and negative predictive 
assuming a probability threshold of greater 1 in 250 to 
reflect the more recent prevalence figures for familial 
hypercholesterolaemia in the general population.3
In a sensitivity analysis to further enhance the accuracy 
of the FAMCAT algorithm, we assessed the benefit of 
using lipid measurements (total cholesterol, LDL 
cholesterol, and triglycerides) and age as continuous 
variables, with an interaction term to specify whether the 
measurement was either total cholesterol or LDL 
cholesterol. Normality was assessed by the Kolmogorov-
Smirnov test and, if found to be significant, the variables 
were log-transformed before inclusion in the multivariable 
model. Personal history of premature myocardial 
infarction (as this features in the DLCN criteria), which the 
primary FAMCAT algorithm does not include, was also 
included in the model. Premature myocardial infarction 
was defined as having an event before the age of 55 years 
for men and before the age of 60 years for women.
We used MedCalc software, version 18.11.6, to estimate 
the sample size.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all of the data and the final responsibility for the decision 
to submit for publication.
Results
Of the 750 000 patients who registered at participating 
primary care facilities between Jan 1, 1999, and 
Sept 1, 2017, 3000 patients were excluded because 
of having other inherited lipid disorders or having all of 
their cholesterol measurements after a diagnosis of 
familial hypercholesterolaemia. There were 1219 cases 
(0·2%) of familial hypercholesterolaemia in the study 
cohort (table 1). 
The mean highest total cholesterol was slightly higher in 
women (5·8 mmol/L [SD 1·3]) than in men (5·6 mmol/L 
[1·2]). The mean highest LDL cholesterol (3·2 mmol/L 
[SD 1·1] in men and 3·2 mmol/L [1·0] in women) was the 
same for both sexes. The majority of the sample were of 
white ethnicities (189 239 [52·2%] of 362 769 men and 
210 914 [54·9%] of 384 231 women). 11 300 (3·1%) of 
362 769 men and 13 499 (3·5%) of 384 231 women had a 
family history of myocardial infarction. Secondary causes 
of hypercholesterolaemia such as diabetes (54 680 [15·1%] 
of 362 769 men and 44 834 [11·7%] of 384 231 women) and 
chronic kidney disease (32 551 [9·0%] of 362 769 men and 
43 911 [11·4%] of 384 231 women) were common.
Figure 1: AUROCs derived from the external validation cohort (n=747 000) for FAMCAT subgroup analysis 
Higher area under the curve (c statistic) confers better discrimination. AUROC=area under the receiver operating curve. FAMCAT=familial hypercholesterolaemia case 
ascertainment tool.
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External validation of the FAMCAT model in QResearch 
showed a high level of discrimination (AUROC 0·832, 
95% CI 0·820–0·845; table 2). FAMCAT showed 
significantly better discrimination than Simon-Broome 
criteria (AUROC 0·694, 95% CI 0·681–0·703), DLCN 
criteria (0·724, 0·710–0·738), and MEDPED criteria 
(0·624, 0·609–0·638). The new NICE recommendation 
of screening for cholesterol concentration higher than the 
99th percentile showed poor discrimination (AUROC 
0·581, 95% CI 0·570–0·591). See the appendix p 2 for 
AUROCs stratified by sex.
The accuracy of FAMCAT for prediction of familial 
hypercholesterolaemia by ethnic group resulted in 
discrimination ranging from 0·767 (95% CI 0·638–0·905) 
for the Asian, Asian British, or other Asian group 
(n=11 372) to 0·887 (0·827–0·947) for the mixed or 
multiple ethnic group (n=34 301; figure 1). In the largest 
group represented—white, white British, or other white 
ethnic (n=400 153)—discrimination was identical to the 
overall discrimination of FAMCAT. There were also a 
large number of individuals (n=255 282) without any 
documented ethnicity in their electronic primary care 
records.
The model showed good calibration across most deciles 
between observed and predicted cases, with some under 
prediction of cases in the highest decile (table 3). There 
was an expected sharp increase in observed and predicted 
cases in the highest decile of predicted probability where 
752 cases were observed and 638 cases were predicted.
In terms of case finding in primary care practice, we 
considered a threshold corresponding to the estimated 
frequency of familial hypercholesterolaemia in the 
general population between 1 in 500 and 1 in 250. Using a 
cutoff above 1 in 500 (0·002), FAMCAT achieved a 
sensitivity of 84% (1028 predicted cases vs 1219 observed 
cases) and specificity of 60% (443 949 predicted non-cases 
vs 745 781 observed non-cases), with a corresponding 
positive predictive value of 0·84% and a negative 
predictive value of 99·2%. Using a cutoff above 
1 in 250 (0·004) in a post-hoc analysis, FAMCAT achieved 
a sensitivity of 72% (878 predicted cases vs 1219 observed 
cases) and specificity of 84% (624 349 predicted non-cases 
vs 745 781 observed non-cases), with a corresponding 
positive predictive value of 1·8% and a negative predictive 
value of 98·2%.
Probability of familial 
hypercholesterolaemia
Observed cases Predicted cases
1 (lowest decile) 0·0002 19 12
2 0·0003 18 17
3 0·0004 28 27
4 0·0006 25 36
5 0·0007 53 76
6 0·0010 51 31
7 0·0015 81 125
8 0·0016 53 114
9 0·0035 139 144
10 (highest decile) 0·1753 752 638
FAMCAT=familial hypercholesterolaemia case ascertainment tool. 
Table 3: FAMCAT model calibration of observed versus predicted cases of familial hypercholesterolaemia 
in the external validation cohort by deciles of predicted probability
Men 
(n=362 769)
Women 
(n=384 231)
Highest cholesterol recorded, mmol/L
If LDL cholesterol measured 2·57 (2·43–2·73) 3·29 (3·13–3·47)
If total cholesterol measured 1·70 (1·61–1·80) 1·95 (1·83–2·07)
Age during cholesterol measurements, years 0·97 (0·96–0·98) 0·99 (0·98–1·00)
Log triglycerides during cholesterol measurement, mmol/L 0·16 (0·13–0·19) 0·08 (0·06–0·09)
Lipid-lowering drugs prescribed during cholesterol measurement*
Prescribed fibrate, bile acid sequestrant, or nicotinic acid 7·03 (2·42–20·36) 3·98 (1·20–13·28)
Prescribed low-potency statin† 1·03 (0·25–4·18) 3·54 (1·72–7·30)
Prescribed medium-potency statin‡ 1·64 (1·29–2·41) 1·72 (1·03–2·87)
Prescribed high-potency statin§ 1·75 (0·79–3·91) 2·55 (1·32–4·91)
Previously history of premature myocardial infarction*|| 2·30 (1·49–3·53) 1·54 (0·79–3·00)
Family history of familial hypercholesterolaemia* 6·74 (3·98–11·39) 2·49 (1·46–2·25)
Family history of myocardial infarction* 3·53 (2·24–5·57) 4·37 (3·17–6·04)
Family history of raised cholesterol* 2·80 (1·69–4·64) 2·12 (1·40–3·22)
Diabetes diagnosis* 0·25 (0·13–0·46) 0·46 (0·29–0·74)
Chronic kidney disease diagnosis* 0·77 (0·46–1·32) 0·17 (0·10–0·30)
Data are adjusted odds ratios (95% CI). Full regression coefficients are presented in the appendix p 3. FAMCAT=familial 
hypercholesterolaemia case ascertainment tool. *Compared with reference group (odds ratio 1). †Fluvastatin or 
pravastatin 40 mg per day, or  simvastatin 10 mg per day. ‡Fluvastatin or pravastatin 80 mg per day, simvastatin 
20–40 mg per day, atorvastatin 10 mg per day, or rosuvastatin 5 mg per day. §Simvastatin 80 mg per day, atorvastatin 
20 mg per day, or rosuvastatin 10 mg per day. ||Premature defined as younger than 55 years in men and younger than 
60 years in women.
Table 4: Adjusted odds ratios from logistic regression model of FAMCAT with continuous values for all 
lipid measurements and age with inclusion of personal history of premature myocardial infarction
Figure 2: AUROCs derived from the external validation cohort (n=747 000) 
for FAMCAT sensitivity analysis 
Higher area under the curve (c statistic) confers better discrimination. 
AUROC=area under the receiver operating curve. FAMCAT=familial 
hypercholesterolaemia case ascertainment tool.
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In the sensitivity analysis, cholesterol concentrations, 
being prescribed lipid-lowering drugs, history of premature 
myocardial infarction, and having a family history of 
myocardial infarction, familial hypercholesterolaemia, or 
raised cholesterol significantly increased likelihood that an 
individual has familial hypercholesterolaemia (table 4). 
Increasing triglyceride concentration and age, and presence 
of secondary causes of hypercholesterolaemia (diabetes or 
chronic kidney disease), decreased the likelihood that 
an individual has familial hypercholesterolaemia because 
these factors are more likely to indicate a non-inherited 
cause of raised cholesterol (table 4).
In terms of discrimination, this sensitivity analysis 
model also further enhanced accuracy of overall 
performance by 4% compared with FAMCAT assessed in 
the primary analysis, with an AUROC of 0·871 (95% CI 
0·859–0·883; figure 2).
Discussion
We have validated a clinical case-finding algorithm 
(FAMCAT) to improve the identification of patients 
at highest likelihood of having familial hyper- 
cholesterolaemia in primary care. In this large 
retrospective cohort study, we found that FAMCAT had 
high predictive accuracy to identify such cases by using 
routinely available variables in patients’ electronic health 
records. FAMCAT was also more accurate than currently 
available and recommended approaches to identify 
cases of possible familial hypercholesterolaemia using 
diagnostic criteria or very high total cholesterol (which 
results in a large absolute number of patients with familial 
hypercholesterolaemia who are not identified). The 
algorithm also performed well across ethnic groups in the 
general primary care population, albeit with some 
variation in predictive accuracy among ethnic minority 
groups. The addition of previous personal history of 
premature myocardial infarction, and fitting a model with 
total cholesterol, LDL cholesterol, triglycerides, and age as 
continuous variables significantly improved FAMCAT 
predictive accuracy even further.
The current external validation of this algorithm has 
been achieved in 747 000 randomly selected patients (from 
the QResearch database) registered with primary care 
practices, independent of the CPRD database from which 
the FAMCAT algorithm was developed. To our knowledge, 
this is the only algorithm for clinical case finding of 
familial hypercholesterolaemia in primary care to be 
robustly developed and stringently validated using two 
separate and similarly large-sized cohort studies. 
Including previous development (about 2·2 million 
patients) and internal validation (about 742 000 patients) 
cohorts, FAMCAT has now been applied to almost 
3·7 million patients—ie, 7% of the UK adult population.
The strong performance and consistent predictive 
accuracy of the FAMCAT algorithm, with high 
discrimination values of 0·83 (in this study) and 0·8615 
in two separate databases, is not surprising because its 
development, internal validation, and current external 
validation have been in very large primary care patient 
populations. In line with other robustly developed 
disease prediction algorithms, we have demonstrated 
consistent predictive accuracy in two independent 
databases. This finding supports the potential benefits 
that FAMCAT might offer in using electronic health 
records to case find patients with the highest likelihood 
of having familial hypercholesterolaemia.
Other strengths of this study include its longitudinal 
design, with a long duration of follow-up, repre- 
sentativeness, and lack of selection, recall, and 
respondent bias. The QResearch database used here is, 
to the best of our knowledge, the world’s largest primary 
medical care database, from which several well 
established clinical algorithms have been developed and 
validated.21–23
Nevertheless, we acknowledge limitations shared in 
common with these other risk algorithms and large 
database analyses.23–25 These limitations include lack of 
formal adjudication of diagnoses, information bias, and 
potential bias due to missing data. The specific coding 
of familial hypercholesterolaemia used will include 
individuals with a diagnosis of familial hyper- 
cholesterolaemia by a lipid specialist using clinical 
diagnostic criteria or genetic testing because there are 
currently no distinct codes for either in clinical systems. 
Furthermore, some patients with phenotypic familial 
hypercholesterolaemia might not have a monogenic 
mutation identified, but conditions such as polygenic 
familial hypercholesterolaemia or familial combined 
hyperlipidaemia.26 Concordance between phenotypic 
criteria (DLCN, Simon Broome, or MEDPED) and 
familial hypercholesterolaemia-causing mutations is 
moderate.27 FAMCAT is designed to identify cases with a 
clinical phenotype indicating the highest likelihood of 
existing disease and therefore to reduce atherosclerotic 
risk of such cases irrespective of a confirmed mutation. 
For such case finding in the general primary care 
population, and for validation in this context, the 
outcome of interest is thus the clinical phenotype for 
familial hyper- cholesterolaemia. Ascertainment bias, 
although not unique to this condition or database 
analyses, should also be noted because some patients 
with familial hypercholesterolaemia might be 
misclassified, have not yet been identified, or might not 
have had cholesterol assessed.15
We note that family history, which is a prerequisite 
for all familial hypercholesterolaemia case-finding 
approaches, is often under-reported in electronic health 
records and more detailed free-text notes could not be 
accessed because of privacy laws. Although the accuracy 
of FAMCAT in detecting familial hypercholesterolaemia 
in various ethnicities in the cohort was good, the study 
population mainly comprised white Europeans, and 
therefore its applicability to other ethnic groups needs 
further exploration. Finally, there was a lower prevalence 
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of familial hypercholesterolaemia (0·2%) seen in this 
cohort compared with more recent evidence suggesting 
general population prevalence of 0·4%.28 This difference 
is probably due to general practioners offering cholesterol 
testing to older patients with comorbidities, and vascular 
and secondary risk factors as part of the NHS vascular 
check programme.29
Three other electronic health record tools exist 
for familial hypercholesterolaemia case finding.30–32 
TARB-ex32 developed in Australia and SEARCH in the 
USA31 are based on DLCN criteria. Both apply specialist 
lipid clinic criteria and scoring to primary care by, for 
example, using natural language processing to extract 
family history of coronary heart disease from records.31 
Another algorithm developed from the Dutch familial 
hypercholesterolaemia screening cohort showed similar 
discrimination to FAMCAT and was validated using a 
separate lipid clinic cohort.30 However, this study involved 
more selected patient populations, already referred to 
specialists with suspected familial hypercholesterolaemia. 
Other research applying specialist Simon Broome 
diagnostic criteria for case finding in primary care found 
that as many as 2·3% of all patients (more than 10-fold 
expected frequency of familial hypercholesterolaemia) 
would require referral for further assessment.13 By 
contrast, FAMCAT has been designed specifically for 
clinical case finding in primary care, to most effectively 
identify people at the highest probability of familial 
hypercholesterolaemia, who should then be appropriately 
further referred for specialist assessment and diagnosis. 
With about 80% of people affected by familial 
hypercholesterolaemia currently undiagnosed, improving 
detection of this life-limiting condition should be a 
public health priority.3,5 The current study underlines the 
poor predictive accuracy of using very elevated cholesterol 
concentrations alone for case finding in the general 
population. Other recommended approaches, such as 
additional use of family history of premature coronary 
heart disease based on Simon Broome criteria, identify 
too many people as having possible familial 
hypercholesterolaemia who will not have the condition.13 
Internationally, use of specialist DLCN or MEDPED 
criteria are recommended.11,12 However, the current study 
and our previous study15 show FAMCAT has better 
predictive accuracy for clinical case finding than any of 
these approaches, and in very large primary care 
populations.
In the UK, FAMCAT has become an automated 
tool for case finding of possible familial hyper- 
cholesterolaemia in primary care records and is being 
updated to reflect improvements in accuracy from using 
continuous lipid measurements and inclusion of 
personal history of premature myocardial infarction. 
Full release of the regression coefficients and variable 
code definitions will allow researchers to independently 
implement the algorithm within their own respective 
populations.
Using routine search of electronic health records, 
FAMCAT can be applied in real time to all adult patients 
registered to a general practice or clinic who have had their 
cholesterol measured previously. Adult patients who 
have a high FAMCAT probability of having familial 
hypercholesterolaemia can be referred for specialist 
assessment (see clinical examples in appendix p 4). 
Subsequent lipid specialist assessment of cases identified 
by this approach is required for diagnostic confirmation, 
which might also include genetic testing and screening of 
relatives. Once the index case is identified with familial 
hyper cholesterolaemia, lipid therapies can be appropriately 
optimised (high-potency statins), and cholesterol testing 
and cascade screening of unidentified relatives can occur, 
an approach that has been shown to be cost-effective.33
Systematically searching electronic health records with 
information technology tools that identify patients at high 
risk could complement current opportunistic practice.34 
Other promising methods of screening for familial 
hypercholesterolaemia in primary care include screening 
children with elevated cholesterol for familial hyper- 
cholesterolaemia and cascade testing parents.35 These 
approaches, along with FAMCAT, could potentially greatly 
enhance familial hypercholesterolaemia iden tification in 
the community. Our further research is prospectively 
evaluating whether FAMCAT improves familial hyper- 
cholesterolaemia detection rates confirmed by genetic 
testing and determining the cost-effectiveness of FAMCAT.
In conclusion, when applied to a large independent 
cohort of patients, the FAMCAT algorithm performs well 
and with greater accuracy than currently recommended 
approaches to identify familial hypercholesterolaemia 
in primary care. FAMCAT has great potential to 
improve case finding for familial hypercholesterolaemia 
and enhance detection of undiagnosed familial hyper- 
cholesterolaemia in the general population.
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